PTEN 和 NM23 抑癌基因与 T1 期乳腺癌患者临床结局的相关性。
Correlation Between Onco-suppressors PTEN and NM23 and Clinical Outcome in Patients With T1 Breast Cancer.
机构信息
Pietro Valdoni Department of Surgery, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy;
Department of Radiological Sciences, Oncology and Pathology, Sapienza University, Rome, Italy.
出版信息
In Vivo. 2021 Jan-Feb;35(1):169-174. doi: 10.21873/invivo.12245.
BACKGROUND
The aim of the present work was to evaluate the prognostic significance in patients with T1 breast cancer of tissue expression of the two oncosuppressors phosphatase and tensin homolog (PTEN) and non-metastatic clone 23 (NM23) as detected by immunohistochemistry.
MATERIALS AND METHODS
We prospectively analyzed 62 patients who underwent surgery for a T1 stage breast cancer. Expression of PTEN and NM23 was tested for correlation with clinical characteristics and clinical outcome.
RESULTS
Of the 62 patients considered for our study, 16 underwent mastectomy and 46 underwent conservative surgical treatment. The surgery was considered radical (R0) in all cases described. PTEN and NM23 expression was higher in patients with no lymph node metastases and no recurrent cancer at a mean follow-up of 36 months (range=6-48 months). This correlation was more evident when both PTNE and NM23 expression were highly expressed (p<0.0001).
CONCLUSION
Low or lack of PTEN and NM23 immunohistochemical expression in cancer tissue is a risk factor for lymph node involvement and recurrent disease. It may represent a valid prognostic factor in planning therapy in patients who had surgery for T1 breast cancer.
背景
本研究旨在通过免疫组化检测抑癌基因磷酸酶和张力蛋白同源物（PTEN）和非转移性克隆 23（NM23）的组织表达，评估其在 T1 期乳腺癌患者中的预后意义。
材料与方法
我们前瞻性分析了 62 例接受 T1 期乳腺癌手术的患者。检测了 PTEN 和 NM23 的表达，以评估其与临床特征和临床结局的相关性。
结果
在我们的研究中，62 例患者中有 16 例行乳房切除术，46 例行保留乳房的手术。所有病例的手术均为根治性（R0）。在平均随访 36 个月（6-48 个月）时，无淋巴结转移和无复发性癌症的患者中，PTEN 和 NM23 的表达更高。当 PTEN 和 NM23 的表达均高时，这种相关性更为明显（p<0.0001）。
结论
肿瘤组织中低表达或缺乏 PTEN 和 NM23 的免疫组化表达是淋巴结受累和疾病复发的危险因素。它可能是 T1 期乳腺癌患者手术治疗后计划治疗的一个有效的预后因素。
Zotero 插件